Loading
Cancer, Hypoxia, and Metabolism / Immune Cells in Cancer / Cancer Research and Treatments · Journal article
Cancer Biome and Targeted Therapy · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of immune cell metabolic reprogramming in the tumor microenvironment, synthesizing mechanistic knowledge across glutamine, fatty acid, and lactate pathways. The authors identify metabolic heterogeneity, limited clinical validation, and the absence of standardized biomarkers as major translational barriers, rather than reporting new empirical evidence or clinical outcomes.
Journal article. Conceptual review spanning major immune cell populations (antitumor and immunosuppressive subsets) in the tumor microenvironment across multiple tumor types and disease stages; no primary study population.
Metabolic reprogramming drives functional exhaustion of antitumor immune cells and promotes immunosuppressive populations in the TME Competition for nutrients, hypoxia, and immunosuppressive metabolite accumulation reshape the metabolic landscape and drive immune evasion and therapeutic resistance Therapeutic strategies targeting glutamine, fatty acid, and lactate metabolism are discussed, with emphasis on interactions with immune checkpoint blockade
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies a mechanistic research agenda rather than providing evidence for clinical practice change. It highlights the need for biomarker-guided metabolic intervention strategies and precision immunometabolism, but notes that clinical validation remains limited and standardized approaches are lacking.
This is a narrative review synthesizing mechanistic understanding of immune metabolism in cancer, raising translational questions rather than reporting empirical results or clinical outcomes.
This review identifies a mechanistic research agenda rather than providing evidence for clinical practice change. It highlights the need for biomarker-guided metabolic intervention strategies and precision immunometabolism, but notes that clinical validation remains limited and standardized approaches are lacking.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic reprogramming is a fundamental regulator of immune cell fate and function in the tumor microenvironment (TME), though the relative contributions of individual metabolic pathways vary across immune cell subsets, tumor types, and disease stages. Competition for nutrients, hypoxia, and the accumulation of immunosuppressive metabolites reshape the TME's metabolic landscape, driving functional exhaustion of antitumor immune cells while promoting the persistence of immunosuppressive populations. These metabolic adaptations have emerged as critical determinants of immune evasion, therapeutic resistance, and responses to cancer immunotherapy. In this review, we examine immune cell metabolism from four complementary perspectives: the physiological metabolic programs of major immune cell populations and their remodeling within the TME; the functional consequences of metabolic reprogramming for antitumor immunity; the principal metabolic drivers, including hypoxia, nutrient competition, and suppressive metabolites; and current therapeutic strategies targeting key immunometabolic pathways, with particular emphasis on glutamine, fatty acid, and lactate metabolism. We further discuss emerging metabolic modulators, their interactions with immune checkpoint blockade, and the opportunities and limitations of combining metabolic intervention with established cancer therapies. Finally, we highlight major translational challenges, including metabolic heterogeneity, limited clinical validation, biomarker identification, and the need for standardized metabolomic and single-cell approaches to enable precision immunometabolism. A more comprehensive understanding of immune cell metabolic regulation may facilitate the development of biomarker-guided therapeutic strategies that selectively restore antitumor immunity while minimizing systemic toxicity, thereby advancing the next generation of personalized cancer immunotherapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.